GlassScriptPhysician profile
Barry Migicovsky
NPI 1316948797
$206,071.08
in general payments reported to CMS, 2019-2025
41 companies · $37K in 2025
The $37K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $20K · 2021: $13K · 2022: $20K · 2023: $14K · 2024: $68K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Food and Beverage: $11K · Travel and Lodging: $7,491 · Honoraria: $4,569 · Consulting Fee: $1,470 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,746.50 |
| Food and Beverage | $11,376.51 |
| Travel and Lodging | $7,491.21 |
| Honoraria | $4,568.75 |
| Consulting Fee | $1,470.00 |
| Education | $105.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $67,248.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $61,047.07 | 2019-2025 | Epclusa |
| Abbvie INC. | $35,187.26 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $27,580.67 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $5,296.04 | 2019-2025 | Ocaliva |
| Olympus Corporation | $2,310.00 | 2022-2023 | Evis Exera III Video System Center |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,045.49 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $939.03 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Genzyme Corporation | $694.18 | 2022-2025 | |
| Qol Medical, LLC | $599.97 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $418.75 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $349.35 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $327.23 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $244.58 | 2019-2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $243.55 | 2023-2025 | Iqirvo, Bylvay |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $234.78 | 2023 | Endoflip |
| Celltrion USA INC. | $231.90 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $229.64 | 2022-2025 | Dupixent |
| Pfizer INC. | $221.96 | 2019-2025 | |
| Lilly USA, LLC | $191.40 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $148.40 | 2019-2020 | |
| Braintree Laboratories, INC. | $136.39 | 2019-2025 | Suflave, Sutab |
| Novo Nordisk INC | $130.73 | 2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Merck Sharp & Dohme LLC | $114.89 | 2021-2024 | Dificid, Zinplava |
| Aimmune Therapeutics, INC. | $110.49 | 2023-2025 | Zenpep |
| Daiichi Sankyo INC. | $106.07 | 2019-2020 | |
| Allergan, INC. | $73.69 | 2019-2020 | |
| Shionogi INC | $71.77 | 2019-2020 | |
| Dova Pharmaceuticals | $67.33 | 2019-2020 | |
| Amgen INC. | $47.83 | 2021 | |
| Olympus America INC. | $47.74 | 2023 | Endoclot Phs |
| Redhill Biopharma INC. | $40.91 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $39.21 | 2021 | |
| Vivus LLC | $36.72 | 2021-2024 | Qsymia |
| Endo Pharmaceuticals INC. | $33.18 | 2019-2022 | |
| Pharmacosmos Therapeutics INC. | $24.66 | 2023 | Monoferric |
| Alfasigma USA, INC. | $21.40 | 2020 | |
| Evoke Pharma, INC. | $18.91 | 2023 | Gimoti |
| Ucb, INC. | $17.84 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $16.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Migicovsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.